Advanced Regenerative Center - ARC STEM CELLS
| トルコ | オーストリア | スペイン | |
| 胚性幹細胞治療 | から $15,000 | から $15,000 | から $20,000 |
Bookimedは胚性幹細胞治療価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。到着時にクリニックで胚性幹細胞治療代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。胚性幹細胞治療で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。胚性幹細胞治療の旅路でお一人になることはありません。
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.
Dr. Natthaphon Suwan, M.D., M.Sc., ABAARM, focuses on Anti-Aging & Regenerative Medicine. He earned his M.D. from Chiang Mai University in 2012. He completed an M.Sc. in Anti-Aging & Regenerative Medicine at Dhurakij Pundit University in 2019. He also received a Master of Management in Health from Mahidol University in 2020. Languages: Thai and English.
Board certifications: WOSAAM Board Diploma (2018); ABAARM/A4M (2019); Thai Board of Preventive Medicine, Public Health (2020). Professional memberships: WOSAAM, A4M, PMAT, CMAT, ACTTHAI, and TIMA.
Current practice: BAAC (2019–present), Vejthani Q Life (2019–present), and UM The Exclusive Health Clinic (2020–present). Previous roles: Vibharam Hospital and World Medical Hospital. Clinical interests: IV therapies, ozone therapy, colon hydrotherapy, male hormones and TRT, PRP, stem cells, genetic cancer risk and NK cell therapy, food intolerance testing, and personalized supplementation. Additional training: A4M (2018–2019), CMAT (2019), ACTTHAI (2019), and H.E.A.T. (2020).